Summary by Ground NewsThe FDA's Cellular, Tissue, and Gene Therapies advisory committee met June 9-10 to consider the two products. The votes each day were unanimously in favor of the products. If approved, beti-cel will be the first potentially curative gene therapy for transfusion-dependent beta-thalassemia.
2 months ago
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Time & Location
Sources are mostly out of (0)
No sources with tracked biases.
See less detail